We are open as normal during COVID-19 pandemic. Order online, same day shipping out.

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 564360


Description: V4-015 is a potent inhibitor of FGFR4 kinase activity.

Price and Availability

Size Price Shipping out time Quantity
Inquire bulk and customized quantity

Pricing updated 2020-06-06. Prices are subject to change without notice.

V4-015 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 564360
Name: V4-015
Chemical Formula: C26H30ClN9OS
Exact Mass: 551.1983
Molecular Weight: 552.1
Elemental Analysis: C, 56.56; H, 5.48; Cl, 6.42; N, 22.83; O, 2.90; S, 5.81

Synonym: V4015; V4 015; V4-015

IUPAC/Chemical Name: 2-(4-(6-Chloro-2-(4-(4-methylpiperazin-1-yl)phenyl)-3H-imidazo[4,5-b]pyridin-7-yl)piperazin-1-yl)-N-(thiazol-2-yl)acetamide


InChi Code: InChI=1S/C26H30ClN9OS/c1-33-7-11-35(12-8-33)19-4-2-18(3-5-19)24-31-22-23(20(27)16-29-25(22)32-24)36-13-9-34(10-14-36)17-21(37)30-26-28-6-15-38-26/h2-6,15-16H,7-14,17H2,1H3,(H,28,30,37)(H,29,31,32)


Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:


1: Ho HK, Németh G, Ng YR, Pang E, Szántai-Kis C, Zsákai L, Breza N, Greff Z, Horváth Z, Pató J, Szabadkai I, Szokol B, Baska F, Őrfî L, Ullrich A, Kéri G, Chua BT. Developing FGFR4 inhibitors as potential anti-cancer agents via in silico design, supported by in vitro and cell-based testing. Curr Med Chem. 2013;20(10):1203-17. PubMed PMID: 23409720.